mRNA regulations

mRNA Regulatory Landscape

David Alvaro, Ph.D.; April Stanley, MS MBA

Pharma's Almanac

cell therapy

Survey of Cell Therapy Formats

Sophie Lutter, Ph.D.

Lab Thread

cell therapy

The Expanding Role of Living Cell Treatments

Sophie Lutter, Ph.D.

Lab Thread

history cell therapy

History of Cell Therapies

Sophie Lutter, Ph.D.

Lab Thread

mRNA analytics

The mRNA Therapeutics Analytical Landscape

David Alvaro, Ph.D.; April Stanley, MS MBA

Pharma's Almanac

cell therapy

Core Analytical Frameworks in Cell Therapy Quality Control

April Stanley, MS MBA

Nice Insight

Viral vectors

Introduction to Viral Vectors for Gene Therapy

April Stanley, MS MBA

Nice Insight

mRNA / Analytics

Analytical Landscape of Viral Vectors

April Stanley, MS MBA

Nice Insight

Market Drivers

mRNA Therapeutics Market

April Stanley, MS MBA

Nice Insight

Market Drivers

Market Drivers of the RNA Landscape

April Stanley, MS MBA; David Alvaro, Ph.D.

Nice Insight

Market Drivers

Global Biopharmaceutical Market Trends

April Stanley, MS MBA

Nice Insight

CGT Patents

The Patent Landscape and its Implications: Cell and Gene Therapies

April Stanley, MS MBA

Nice Insight

Pathfinder

AAV vs. Non-Viral Gene Delivery: Which Is Better for In Vivo Gene Therapy?

Nice Insight

RNA

Is mRNA a Gene Therapy? Unpacking the Evolving Regulatory Debate

April Stanley, MS MBA; Cynthia A. Challener, Ph.D.

Nice Insight

Biomarkers

The Biomarker Revolution in Medicine and Drug Development

David Alvaro, Ph.D.

Pharma's Almanac

cell therapy

State of the Cell and Gene Therapy Market

James Grote

Nice Insight

Column: M&A

Why the Big Shifts in Gene Therapy Investments? It’s Late in the Game

Nigel Walker

Nice Insight

YEAR REVIEW

2021 Roundup: The Year of Cell and Gene Therapy

David Alvaro, Ph.D.

Pharma's Almanac

MANUFACTURING

CAR-T Cell and Gene Therapy Market: Challenges and Opportunities

Jason Rahal

Nice Insight

Supply Chain

Delivering Vaccines During a Pandemic

Nigel Walker

Nice Insight